Recent update in FDA label indication In December 2022, FDA expanded semaglutides label to include pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex
L-Glycine and NAC contribute to normal antioxidant defense and energy metabolism
Semaglutide falls under a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1s, which mimic the GLP-1 hormone that is produced in the gut after eating
Test-retest reliability of performing upper and lower body strength assessments in our laboratory on resistance-trained participants showed low day-to-day mean coefficients of variation (CVs) and high reliability for the bench press (5.2%, intraclass, r =0.98) and leg press (7.4%, intraclass, r =0.97)
Reddy's Laboratories, SUN PHARMA, Zydus Group, Alkem Laboratories Ltd., Biocon, Cipla and others are gearing up to capture this space through branded generics, potentially adding 0.5-1% to overall IPM growth in FY27
The free T3 level will also be relatively constant
